Cabaletta Bio Inc. reported its third quarter 2025 financial results and provided a business update. The company highlighted progress in its RESET™ clinical development program, including the presentation of rese-cel data at multiple medical meetings showing potentially transformative, drug-free clinical responses with a favorable safety profile for autoimmune patients. All myositis patients in the Phase 1/2 DM/ASyS cohort with sufficient follow-up who would have met key criteria for the registrational cohort achieved the 16-week primary endpoint. The company plans a BLA submission for rese-cel in 2027, based on a 14-patient, single-arm DM/ASyS registrational cohort, which is starting enrollment this quarter within the RESET-Myositis™ trial. FDA alignment on additional registrational cohort designs for RESET-SSc™ and RESET-SLE™ is anticipated by year-end 2025. For the three months ended September 30, 2025, research and development expenses were $39.8 million, compared to $26.3 million for the same period in 2024. General and administrative expenses were $6.8 million, unchanged from the same period in 2024. As of September 30, 2025, Cabaletta had cash, cash equivalents, and short-term investments of $159.9 million, compared to $164.0 million as of December 31, 2024. The company expects its cash position to fund its operating plan into the second half of 2026.